Fostering Research

Jussi J. Saukkonen's commentary (The Scientist, April 13, 1992, page 12) suggests that M.D.-Ph.D. programs "should be regarded as an `insurance premium' paid to protect our substantial research investment," and that such programs can make "the student's commitment to long-term training financially feasible." I believe that this approach begs the question of how to encourage bright students to make biomedical research their career, especially given the statement in the same commentary that such

Written byBruce Stanley
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

I believe that this approach begs the question of how to encourage bright students to make biomedical research their career, especially given the statement in the same commentary that such programs "were never intended to provide the full complement of manpower for medical research."

The "full complement of manpower" can be ensured only by providing hope for at least a somewhat secure financial picture to all prospective scientists.

Most Ph.D. scientists love the intellectual challenge of research and the possibility of contributing to understanding, preventing, and healing diseases. Personal financial gain and security cannot be primary motivators, as most scientists earn considerably less than what they could earn in other fields (including clinical medicine).

Today's insecurity in funding has added a further barrier. People will work for lower pay if they have some assurance that they will be able to do the work they love; however, it is unrealistic to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies